| Today’s Big NewsJun 11, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
| By Kevin Dunleavy Once hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorder. |
|
|
|
By Annalee Armstrong Eli Lilly’s Alzheimer’s treatment sailed through an FDA advisory committee meeting Monday, with panelists praising the therapy as innovative—while also cautioning about a lack of data on specific subgroups. |
By Conor Hale The image-guided therapies unit—a $1.6 billion business previously held under GE HealthCare’s Imaging banner—will instead join up with Ultrasound. |
By Gabrielle Masson Johnson & Johnson Executive Vice President and Chief External Innovation and Medical Officer William Hait, M.D., Ph.D., will be hanging up his hat this September. |
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now. 
|
|
By Gabrielle Masson Amid an organizational reset, Bayer’s SVP and Global Head of Biotech Jens Vogel, Ph.D., has hit the exits after four years with the German pharma. |
By Nick Paul Taylor AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the past, the drugmaker vaulted over many rivals in PatientView’s latest survey to take the second spot on a reputation ranking. |
By Fraiser Kansteiner Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami. |
By Andrea Park In an analysis of thousands of Mallinckrodt’s internal documents, a pair of researchers found evidence of a host of strategies that the pharma allegedly utilized to help sway doctors to prescribe its opioids. |
By Conor Hale The University of Oxford spinout's series A round follows up on positive preliminary data from a first-in-human trial earlier this year. |
By Andrea Park Endo has brought all hands on deck for its newest campaign to raise awareness about Dupuytren’s contracture and its available treatments. |
By Andrea Park Takeda is taking care of its adopted home. The Japanese pharma has extended its longstanding partnership with the nonprofit organization Partners in Health, with a specific focus on promoting health equity in Massachusetts, where it has made its U.S. headquarters. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report. |
|
|---|
|
|
|
Biotech companies must be able to navigate the complexities of development and approval. Learn how to drive improved speed, quality, predictability, and risk management by making key changes. Download now for exclusive insights. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
